TNF antagonism

Authors
McDonnell, ND Abbott, NN Mohler, KM Hansel, TT Kips, JC
Citation
Nd. Mcdonnell et al., TNF antagonism, PROG R RES, 31, 2001, pp. 247-250
Citations number
29
Categorie Soggetti
Current Book Contents
Journal title
NEW DRUGS FOR ASTHMA, ALLERGY AND COPD → ACNP
ISSN journal
14222140
Volume
31
Year of publication
2001
Pages
247 - 250
Database
ISI
SICI code
1422-2140(2001)31:<247:TA>2.0.ZU;2-M
Abstract
TNF antagonists such as soluble p75 receptor constructs and anti-TNF monocl onal antibodies are both currently licensed therapies for the treatment of rheumatoid arthritis (RA). Based on experimental studies in animals and the presence of elevated TNF levels in patients, there is also a strong ration ale for TNF antagonism to be employed in asthma and COPD. In particular, TN F seems to play an important role in determining the severity of asthma. TN F antagonism might therefore be of particular interest for the treatment of severe persistent asthma as well as acute severe exacerbations It might al so constitute a novel anti-inflammatory therapy to control disease progress ion in COPD.